Platelet hyperreactivity and prognosis in survivors of myocardial infarction

New England Journal of Medicine

Volumn 322, Issue 22, 1990, Pages 1549-1554

  Trip, Mieke D ^a   Cats, Volkert Manger ^b   Van Capelle, Frans J L ^a   Vreeken, Johan ^a  

^a Department of Cardiology ^*  (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FEMALE; HEART INFARCTION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE AGGREGATION;

EID: 0025280866     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199005313222201     Document Type: Article

References (30)

1. Ross R. The pathogenesis of atherosclerosis — an update. N Engl J Med 1986; 314:488–500.
2. Davies MJ, Thomas achéal. Plaque fissuring — the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53:363–73.
3. Fuster V, Chesebro JH. Mechanisms of unstable angina. N Engl J Med 1986; 315:1023–5.
4. Davies MJ, Thomas achéal, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73:418–27.
5. Hirsh J. Hyperreactive platelets and complications of coronary artery disease. N Engl J Med 1987; 316:1543–4.
6. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304:685–91.
7. Hughes A, Daunt S, Vass G, Wickes J. In vivo platelet activation following myocardial infarction and acute coronary ischemia. Thromb Haemost 1982; 48:133–5.
8. Mueller HS, Rao PS, Greenberg MA, et al. Systemic and transcardiac platelet activity in acute myocardial infarction in man: resistance to prostacyclin. Circulation 1985; 72:1336–45.
9. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315:983–9.
10. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316:1514–8.
11. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309:396–403.
12. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985; 313:1369–75.
13. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319:1105–11.
14. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349–60.
15. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296:320–31.
16. Vreeken J, van Aken WG. Spontaneous aggregation of blood platelets as a cause of idiopathic thrombosis and recurrent painful toes and fingers. Lancet 1971; 2:1395–7.
17. Preston FE. Aspirin, prostaglandins, and peripheral gangrene. Am J Med 1983; 74:55–60.
18. Ten Cate JW, Vos J, Oosterhuis H, Prenger D, Jenkins CS. Spontaneous platelet aggregation in cerebrovascular disease. Thromb Haemost 1978; 39:223–9.
19. Hoogendijk EM, Jenkins CS, van Wijk EM, Vos J, ten Cate JW. Spontaneous platelet aggregation in cerebrovascular disease II: further characterisation of the platelet defect. Thromb Haemost 1979; 41:512–22.
20. Manger Cats V, van Capelle FJL, Lie KI, Durrer D. Effect of treatment with 2×100 mg metoprolol on mortality in a single-center study with low placebo mortality-rate after infarction. Circulation 1983; 68: Suppl III: III-181. abstract.
21. Born GVR. Aggregation of blood platelets by adenosine disphosphate and its reversal. Nature 1962; 194:927–8.
22. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213–26.
23. BMDP biomedical computer programs. Berkeley: University of California Press, 1983.
24. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35:1–39.
25. Schlant RC, Forman S, Stamler J, Canner PL. The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men: the 5-year findings of the coronary drug project. Circulation 1982; 66:401–14.
26. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309:331–6.
27. Campbell S, A'Hern R, Quigley P, Vincent R, Jewitt D, Chamberlain D. Identification of patients at low risk of dying after acute myocardial infarction, by simple clinical and submaximal exercise test criteria. Eur Heart J 1988; 9:938–47.
28. Olsson G, Rehnqvist N, Sjögren A, Erhardt L, Lundman T. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 1985; 5:1428–37.
29. Lopressor Intervention Trial Research Group. The Lopressor intervention trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J 1987; 8:1056–64.
30. Olsson G, Hjemdahl P, Rehnqvist N. Rebound phenomena following gradual withdrawal of chronic metoprolol treatment in patients with ischemic heart disease. Am Heart J 1984; 108:454–62.